Despite Years of Development, Affymetrix's Dx Partners Slow to Bring Tests to Market | GenomeWeb

By Justin Petrone

Skyline Diagnostics recently gained a CE-IVD Mark for its AMLprofiler leukemia test, making it the fourth test based on the Affymetrix GeneChip platform to be launched in the US and Europe for clinical use since 2005.

And while the array maker's other diagnostic partners have pledged to introduce more tests, it is unclear when many of those assays will become available.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: researchers identify the characteristic genomic features of clear cell renal cell carcinoma, and more.

A technology that has the potential to make species go extinct could be used against the Zika virus. 

University of the Republic postdoc Victor Morais says researchers should be careful of the open access journals they choose to publish in.

If science funding agencies can talk tough about sexual harassers, shouldn't they also put their talk into action?